Basket cover image
16 handpicked stocks

Pets Are Family

The emotional bond with our furry companions has created a powerful, recession-resistant market. These carefully selected companies provide essential veterinary care, nutrition, and wellness services that pet owners prioritize regardless of economic conditions.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+6

Author avatar

Han Tan | Market Analyst

Updated 2 days ago | Published at June 17

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

ZTS

Zoetis Inc.

ZTS

Current price

$153.73

As a global leader in animal health, it develops and commercializes critical medicines, vaccines, and diagnostic products for companion animals.

IDXX

IDEXX Laboratories, Inc.

IDXX

Current price

$638.76

It provides veterinarians with a wide range of advanced diagnostic instruments, software, and services essential for modern pet healthcare.

ELAN

Elanco Animal Health Inc

ELAN

Current price

$17.59

This company offers a broad portfolio of pharmaceuticals and health products to prevent and treat diseases in pets.

About This Group of Stocks

1

Our Expert Thinking

Pet care spending is based on emotional bonds rather than discretionary budgets. When people consider pets as family members, they consistently invest in their health and happiness, creating reliable revenue streams for companies in this space.

2

What You Need to Know

This collection focuses on non-discretionary pet spending that remains stable even during economic downturns. From veterinary services to premium nutrition, these companies benefit from consumers who prioritize their pets' needs regardless of broader financial conditions.

3

Why These Stocks

We've selected market leaders and innovators across the pet care ecosystem. These companies are positioned to benefit from increasing pet ownership and the growing trend of pet insurance adoption, which is expanding the market for sophisticated treatments and services.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+44.65%

Group Performance Snapshot

44.65%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 44.65% over the next year.

12 of 15

Stocks Rated Buy by Analysts

12 of 15 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🐾

Recession-Proof Spending

Pet owners rarely cut back on essential care, making these stocks historically resilient during economic downturns. Their stable performance might offer peace of mind in volatile markets.

💉

Pet Insurance Boom

The explosive growth in pet insurance is creating a ripple effect across the industry, enabling more spending on premium services and treatments that were previously out of reach for many pet owners.

🏠

The Pandemic Pet Surge

Record pet adoptions during lockdowns created millions of new pet owners who will spend on their companions for years to come, fueling long-term growth for companies in this space.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.